Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study "ARC"

Completed

Phase 4 Results N/A

Summary of Purpose

The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 2 February 2015.

1 Oct 2012 30 Nov 2012 1 Oct 2014 1 Oct 2014 1 Feb 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts